- Home
- TPST vs COCH Comparison
TPST vs COCH Comparison
Compare TPST & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- COCH
- Stock Information
- Founded
- TPST 2011
- COCH 1995
- Country
- TPST United States
- COCH United States
- Employees
- TPST N/A
- COCH N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- TPST Health Care
- COCH Finance
- Exchange
- TPST Nasdaq
- COCH Nasdaq
- Market Cap
- TPST 33.0M
- COCH 31.6M
- IPO Year
- TPST N/A
- COCH N/A
- Fundamental
- Price
- TPST $7.13
- COCH $1.57
- Analyst Decision
- TPST Hold
- COCH Strong Buy
- Analyst Count
- TPST 3
- COCH 2
- Target Price
- TPST $30.00
- COCH $9.25
- AVG Volume (30 Days)
- TPST 251.1K
- COCH 19.0K
- Earning Date
- TPST 08-07-2025
- COCH 08-11-2025
- Dividend Yield
- TPST N/A
- COCH N/A
- EPS Growth
- TPST N/A
- COCH N/A
- EPS
- TPST N/A
- COCH N/A
- Revenue
- TPST N/A
- COCH $212,000.00
- Revenue This Year
- TPST N/A
- COCH $8.04
- Revenue Next Year
- TPST N/A
- COCH $15.39
- P/E Ratio
- TPST N/A
- COCH N/A
- Revenue Growth
- TPST N/A
- COCH N/A
- 52 Week Low
- TPST $5.35
- COCH $1.21
- 52 Week High
- TPST $30.03
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- TPST 51.19
- COCH 58.35
- Support Level
- TPST $6.73
- COCH $1.40
- Resistance Level
- TPST $7.18
- COCH $1.53
- Average True Range (ATR)
- TPST 0.31
- COCH 0.09
- MACD
- TPST -0.00
- COCH 0.02
- Stochastic Oscillator
- TPST 84.48
- COCH 99.95
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.